Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
08:34am, Wednesday, 19'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
08:34am, Thursday, 13'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,
ChromaDex to Present at the 37th Annual Roth Conference
04:04pm, Tuesday, 11'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
10:30am, Thursday, 06'th Mar 2025
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
08:53pm, Tuesday, 04'th Mar 2025
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
06:15pm, Tuesday, 04'th Mar 2025
ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
04:02pm, Tuesday, 04'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return
09:05am, Thursday, 20'th Feb 2025
Let's take a look at four stocks, GFF, BGC, CHX and CDXC, with impressive net profit margins for a robust portfolio.
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
08:32am, Monday, 06'th Jan 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
12:51pm, Tuesday, 24'th Dec 2024
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Monday, 09'th Dec 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
08:34am, Tuesday, 03'rd Dec 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual B
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 22'nd Nov 2024
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
